Amir Inamdar - 13 Oct 2026 Form 3 Insider Report for Helus Pharma Inc. (HELP)

Reporting relationship: Director
Issuer ticker: HELP
Reported as of: 13 Oct 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 26 Oct 2026, 11:17:42 UTC
Source filing: View source filing
Reporting owner signature: /s/ Amir Inamdar

Filing notes and source

Key filing fact

Amir Inamdar filed Form 3 for Helus Pharma Inc. (HELP) on 26 Oct 2026.

Key facts

This page summarizes Amir Inamdar's Form 3 filing for Helus Pharma Inc. (HELP).
0 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 26 Oct 2026, 11:17.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002159392 Primary reporting owner

Inamdar Amir

Relationship: Director
Address: C/O HELUS PHARMA INC., 100 KING STREET WEST, SUITE 5600, TORONTO, ONTARIO, CANADA
Signature: /s/ Amir Inamdar
Signature date: 26 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HELP holding

Common Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 224,332
Date: 13 Oct 2026
Ownership: Held by Zephyr Life Sciences Ltd.
Footnotes: F1

HELP holding

Common Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 3,490
Date: 13 Oct 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

HELP holding Derivative

Restricted Share Units

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 13 Oct 2026
Ownership: Held by Zephyr Life Sciences Inc.
Underlying class: Common Shares
Underlying amount: 66,668
Exercise price
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Held by Zephyr Life Sciences Ltd., a United Kingdom corporation owned and controlled by the reporting person.

Footnote F2

On October 1, 2025, the Reporting Person was granted 100,000 restricted share units ("RSUs") which vest as follows: 8,333 RSUs vesting on January 6, 2026, and 8,333 RSUs vesting quarterly over three years on November 20, February 20, May 20, and August 20 until fully vested. As of the date of this Form 3, the Reporting Person holds 66,668 unvested RSUs from the October 2025 grant.

Footnote F3

Each RSU represents a right to receive one Issuer common share.